Skip to content

Opko Health OPK Return on equity

Return on equity at other companies

Quest Diagnostics logo
Quest DiagnosticsDGX
14.3%+0.9pp
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
-42.9%+1.3pp
HRO
HarrowHROW
-50%+17.5pp
Precigen logo
PrecigenPGEN
-843.6%-1,103pp
Immunome logo
ImmunomeIMNM
-50.1%-10.8pp
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-325.6%+36.9pp

Other financials

Income statement

See full
Revenue$124.2M-17.2%
Gross profit$45.8M+7.4%
Operating income-$51.0M+24.0%
Net income-$54.8M+18.9%
EPS (diluted)-$0.07+30.0%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$52.8M-4.2%
Total equity$1.2B-8.2%
Total assets$1.9B-12.8%

Cash flow

See full
Operating cash flow-$19.3M+44.1%
CapEx$1.8M-42.6%
Free cash flow-$21.1M+44.0%

Valuation

See full
Market cap$1.13B+10.0%
P/S1.9×+0.5×

Profitability

See full
Gross margin36%+4.2pp
Operating margin-17.4%-5.6pp
Net margin-36.6%-44.8pp
FCF margin-30%+0.1pp

Returns & leverage

See full
Debt / equity0.0×
Current ratio3.6×+1.1×

Where this comes from

Calculated from Opko Health’s reported figures.

Based on trailing twelve months.

The official record: Opko Health’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opko Health's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opko Health's return on equity?
Opko Health (OPK) reported return on equity of -16.9% in Q1 2026.
How has Opko Health's return on equity changed year-over-year?
Opko Health's return on equity decreased by 456.4% year-over-year, from -3% to -16.9%.
What is the long-term trend for Opko Health's return on equity?
Over 5 years (2020 to 2025), Opko Health's return on equity has grown at a 55.9% compound annual growth rate (CAGR), from 1.9% to -17.1%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.